Comparative Pharmacology
Head-to-head clinical analysis: CYCLAINE versus LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CYCLAINE versus LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE.
CYCLAINE vs LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cyclaine is a local anesthetic that reversibly blocks nerve conduction by decreasing the permeability of the neuronal membrane to sodium ions, thereby stabilizing the membrane and preventing the initiation and transmission of electrical impulses.
Lidocaine is a local anesthetic that stabilizes the neuronal membrane by inhibiting sodium ion channels, thereby blocking the initiation and conduction of nerve impulses. It also exhibits cardiac effects as a class IB antiarrhythmic agent by modulating sodium channels in myocardial cells.
0.2–0.4 mg/kg IV for induction; 0.5–1.5 mg/kg/h IV infusion for maintenance.
1-4 mg/kg via intravenous bolus, not to exceed 300 mg; may be followed by continuous infusion of 1-4 mg/min.
None Documented
None Documented
Terminal elimination half-life: 2-4 hours in adults; prolonged with hepatic impairment.
1.5–2 hours (terminal) in healthy adults; prolonged in hepatic impairment (up to 5–7 hours), heart failure (up to 10 hours), or with continuous infusion (>24 h) due to accumulation. Context: requires monitoring in hepatic or cardiac dysfunction to avoid toxicity.
Renal: minimal (<5% unchanged); biliary/fecal: >70% as metabolites; small amount exhaled as CO2.
Renal: ~90% as metabolites (primarily monoethylglycinexylidide [MEGX] and glycinexylidide [GX]), <10% unchanged. Fecal: <1%.
Category C
Category A/B
Local Anesthetic
Local Anesthetic / Antiarrhythmic (Class Ib)